SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Battalion Oil Corp. engages in the acquisition, production, exploration, and development of liquids-rich oil and natural gas assets in the Delaware Basin. The company was founded in 1987 and is headquartered in Houston, TX.

Battalion Oil Corp - Ordinary Shares (New)

Battalion Oil (BATL) is experiencing a massive surge as escalating geopolitical tensions in the Middle East, including drone strikes on key oil infrastructure, ignite fears of supply disruption and drive up crude prices. The community is buzzing about a potential short squeeze, noting BATL's low float and strong bullish momentum within the broader hot oil and gas sector.

Indonesia Energy Corp. Ltd. operates as an oil and gas, exploration, and production company. It engages in oil and gas assets portfolio with a mix between medium-sized producing blocks and exploration blocks with significant resources. Its portfolio includes Kruh, Citarum, and Rangkas Area. The company was founded by James J. Huang and Wirawan Jusuf in 2014 and is headquartered in Jakarta, Indonesia.

Indonesia Energy Corp Ltd

Indonesia Energy is actively trending as escalating geopolitical tensions in the Middle East, including disruptions to key energy infrastructure and shipping routes, ignite fervent speculation across the oil and gas sector. The community is buzzing with comparisons to past parabolic runs during global conflicts, debating the stock's potential for a significant squeeze and sustained rally amid heightened volatility.

SSgA Active Trust - State Street SPDR S&P 500 ETF Trust

The SPY is trending as it rallies against expectations amid escalating geopolitical tensions involving Iran, baffling many who anticipated a downturn. Community discussions highlight 'war is bullish' and the ongoing 'slaughter' of bears, attributing the resilience to market mechanics designed to crush short positions.

AeroVironment, Inc. engages in the design, development, and production of multi-domain robotic systems and related services for government agencies and businesses. It operates through the following business segments: UnCrewed Systems, Loitering Munitions Systems, and MacCready Work. The UnCrewed Systems segment focuses primarily on small UAS products designed to operate reliably at lower altitudes in a wide range of environmental conditions. The Loitering Munitions Systems segment focuses primarily on tube-launched aircraft that deploy with the push of a button, fly at higher speeds than small UAS products, and perform either effects delivery or reconnaissance missions, and related support services including training, spare parts, product repair, and product replacement. The MacCready Works segment focuses on customer-funded research and development in the areas of HAPS, robotics, sensors, software analytics, data intelligence, and connectivity. The company was founded by Paul B. MacCready, Jr. in July 1971 and is headquartered in Arlington, VA.

AeroVironment Inc.

AeroVironment is experiencing extreme volatility and a sharp sell-off following a Raymond James downgrade and news that the US Space Force is re-competing a major contract, sparking intense community debate on whether the market reaction is overdone given robust demand for drone technology.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

The Invesco QQQ Trust is trending as the market exhibits surprising resilience, rallying from earlier lows despite ongoing Middle East conflicts. Many in the community are debating whether this upward movement reflects underlying strength or a heavily manipulated short squeeze.

Venture Global, Inc. engages in the development and construction of liquefied natural gas production, establishing us as a rapidly growing company delivering critical LNG to the world. It projects include Calcasieu, Plaquemines, CP2, CP3 and Delta projects. The company was founded by Michael Sabel and Robert Pender in 2023 and is headquartered in Arlington, VA.

Venture Global Inc. - Ordinary Shares - Class A

Venture Global Inc

Venture Global is seeing intense discussion following its strong Q4 earnings and new LNG agreements, with investor attention acutely focused on escalating Middle East tensions that have halted Qatari LNG production and dramatically spiked global natural gas prices. The community is highly bullish, anticipating VG will significantly benefit from its substantial spot market exposure and rapidly expanding capacity amid critical global supply disruptions.

United States Antimony Corp. engages in the extraction, processing and sale of antimony, zeolite, silver, and gold products. It operates through the following segments: United States Antimony Operations, Mexican Antimony Operations, Precious Metals Recovery, and United States Zeolite Operations. The company was founded by John C. Lawrence in June 1968 and is headquartered in Thompson Falls, MT.

United States Antimony Corp.

United States Antimony Corp

Recent analyst upgrades and escalating geopolitical tensions are driving United States Antimony Corp. to trend, with the community highlighting its unique position as the sole domestic antimony producer crucial for military munitions and anticipating significant government contracts and a potential short squeeze.

Rocket Cos., Inc. engages in the provision of a suite of services related to homeownership and other personal financial transactions. It operates through the following segments: Direct to Consumer and Partner Network. The Direct to Consumer segment consists of performance marketing and direct engagement through the Rocket Mortgage App. The Partner Network Segment focuses on partnerships with premier consumer-focused organizations, brokers and mortgage professionals who leverage the platform and scale to provide mortgage solutions to clients. The company was founded by Daniel Gilbert in 1985 and is headquartered in Detroit, MI.

Rocket Companies Inc - Ordinary Shares Class A

Rocket Companies Inc

Rocket Companies is trending after reporting strong earnings and an optimistic outlook, amplified by a strategic alliance with Compass expanding its real estate offerings. The community is actively discussing the stock's potential for increased mortgage origination and refinancing demand as rates ease, with many eyeing its notable short interest for a potential squeeze.

Credo Technology Group Holding Ltd. engages in the development of connectivity solutions and products for the data infrastructure market. Its products include integrated circuits, active electrical cables, and SerDes chiplets. The company was founded by Chi Fung Cheng and Yat Tung Lam on 2008 and is headquartered in George Town, Cayman Islands.

Credo Technology Group Holding Ltd

Credo Technology is trending following a significant pre-announcement of Q3 revenue far exceeding guidance and implying massive year-over-year growth, driven by strong demand in AI data center infrastructure. The community is actively debating whether this signals a strong post-earnings rally, especially given soaring hyperscaler CapEx and a new "Buy" rating from Goldman Sachs, or if the stock's recent volatility and prior "sell the news" patterns will persist.

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET Technologies is trending as the optical interconnect sector gains significant traction from NVIDIA's strategic focus, validating POET's crucial role in scaling AI data centers, with the community actively anticipating major partnerships and continued institutional accumulation.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Wall Street Zen Upgrades Iovance Biotherapeutics (NASDAQ:IOVA) to Hold

Wall Street Zen upgraded shares of Iovance Biotherapeutics from a "sell" rating to a "hold" rating in a report on Saturday...

Is Aldeyra Therapeutics (ALDX) Outperforming Other Medical Stocks This Year?

Here is how Aldeyra Therapeutics, Inc. (ALDX) and Iovance Biotherapeutics (IOVA) have performed compared to their sector so far this year.

Brokers Set Expectations for IOVA Q1 Earnings

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA - Free Report) - Stock analysts at HC Wainwright issued their Q1 2026 EPS estimates for Iovance Biotherapeutics in a research report issued to clients and...

Barclays Boosts Iovance Biotherapeutics (NASDAQ:IOVA) Price Target to $11.00

Barclays upped their target price on Iovance Biotherapeutics from $10.00 to $11.00 and gave the company an "overweight" rating in a report on Wednesday...

IOVA Beats on Q4 Earnings & Sales, Stock Soars on Pipeline Progress

Iovance posts narrower Q4 loss as Amtagvi sales jump 33%. Shares soar on 50% ORR data and plans for registrational sarcoma study.

Iovance Biotherapeutics (NASDAQ:IOVA) Sees Strong Trading Volume Following Earnings Beat

Iovance Biotherapeutics (NASDAQ:IOVA) Sees Large Volume Increase on Strong Earnings...

Chardan Capital Has Lowered Expectations for Iovance Biotherapeutics (NASDAQ:IOVA) Stock Price

Chardan Capital lowered their target price on shares of Iovance Biotherapeutics from $17.00 to $16.00 and set a "buy" rating on the stock in a research note on Wednesday...

Iovance Biotherapeutics (NASDAQ:IOVA) Raised to Market Outperform at Citizens Jmp

Citizens Jmp upgraded Iovance Biotherapeutics from a "market perform" rating to a "market outperform" rating and set a $5.00 price target on the stock in a research report on Wednesday...

<ul class="summary-bullets"><li>Chardan reiterated a ‘Buy’ rating and sees 323% upside, despite trimming its price target to $16 from $17.</li><li>Q4 margins hit a record high, with gross margin climbing to 50% from 43% in Q3, which the interim CEO said was Iovance’s “best ever” performance.</li><li>Pipeline momentum strengthened, with FDA Fast Track designation for Lifileucel in nonsquamous lung cancer.</li></ul>Shares of Iovance Biotherapeutics, Inc. (IOVA) posted their best session in two years on Tuesday after the company reported record fourth-quarter (Q4) margins, with investor sentiment buoyed by an analyst rating that implied more than 300% upside from current levels.<a href="https://stocktwits.com/symbol/IOVA">IOVA stock</a> jumped over 30% to $3.78 in Tuesday’s regular session, and added another 0.7% in extended trading.&nbsp;&nbsp;<h2 class="st-heading-2">Chardan Sees Huge Upside For IOVA</h2>On Tuesday, Chardan lowered its price target on Iovance to $16 from $17, implying a 323% upside from current levels, while retaining a ‘Buy’ rating.&nbsp;The brokerage attributed the Q4 margin rise to operational optimization and said further improvements are expected through 2026 as the company internalizes manufacturing of Lifileucel, its immune cell therapy for solid tumors, at its iCTC facility and optimizes research and development spending. It added that Iovance’s pipeline continues to advance, with early data in soft tissue sarcomas “looking encouraging.”<h2 class="st-heading-2">Amtagvi Drives Strong Q4 Revenue Surge</h2>Iovance reported&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-did-iova-stock-gain-pre-market-today/cZRvxIHR4Cc">Q4 revenue</a> of $86.7 million, beating analyst expectations of $81 million, while posting a Q4 loss of $0.18 per share, in line with estimates.Q4 total product revenue rose about 30% from the previous quarter to $87 million, led by about $65 million in U.S. Amtagvi revenue, a cell-based therapy for advanced melanoma, and $22 million from global Proleukin sales, a drug that helps activate the immune system during treatment.Gross margin from cost of sales climbed to 50%, up from 43% in the prior quarter, marking the company’s “best ever” margin performance, according to interim CEO Frederick Vogt, as said on the earnings call.For full-year 2025, Iovance reported total product revenue of about $264 million, coming in within its guidance range of $250 million to $300 million. The company ended the year with $303 million in cash, which is expected to fund operations into the third quarter of 2027.<h2 class="st-heading-2">CEO Sees “Remarkable” Revenue Growth In 2026</h2>Vogt said Iovance achieved its 2025 guidance range in its first full year of commercial launch, driven by rising demand for Amtagvi. On the earnings call, he said the company expects “remarkable revenue growth” in 2026 and sees potential for Amtagvi and Proleukin to generate more than $1 billion in peak U.S. sales.The company noted Amtagvi’s approval in Canada and pending regulatory decisions in the U.K. and Australia in the first half of 2026, with Switzerland targeted for the first half of 2027. Iovance is also working with European regulators to resubmit a marketing authorization application in 2026.<h2 class="st-heading-2">FDA Fast Track Granted For Lifileucel In Lung Cancer</h2>Iovance said Lifileucel has received Fast Track Designation from the FDA for previously treated nonsquamous non-small cell lung cancer, with interim data showing a 26% objective response rate and durability extending beyond 25 months. The company expects to complete enrollment in 2026 and to target an accelerated launch in the second half of 2027.Separately, the company announced positive early data in advanced soft-tissue sarcomas, where Lifileucel delivered a 50% confirmed response rate in an initial cohort of heavily pretreated patients. Iovance plans to initiate a single-arm registrational trial in the second quarter of 2026 and engage with regulators on an accelerated approval pathway.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment for IOVA was ‘extremely bullish’ amid a 550% surge in 24-hour message volume.<figure class="image"><img src="https://news.stocktwits-cdn.com/iova_ss_png_a21e8bee3a.webp" alt="iova ss.png" width="970" height="142"><figcaption>IOVA sentiment and message volume as of February 25 | Source: Stocktwits</figcaption></figure>One user said, “potentially this could help Q1 margins go up further. If they can reach somewhere around 60%, it’ll be great progress towards profitability.”<stembedurl>https://stocktwits.com/ap20190829/message/645806810</stembedurl>Another user said, “THIS IS A 10/ share stock no doubt. You still have time to get it and make hay.”<stembedurl>https://stocktwits.com/ScottyG305/message/645801421</stembedurl>IOVA stock has surged 38% year to date.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the IOVANCE BIOTHERAPEUTICS logo is displayed on the screen of a tablet computer. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

After IOVA Stock’s Best Day In 2 Years, Analyst Sees Over 300% Upside: Here’s Why

Shares of Iovance Biotherapeutics, Inc. (IOVA) posted their best session in two years on Tuesday after the company reported record fourth-quarter (Q4) margins

Equity

Chardan cited operational efficiencies and expected margin lift as Lifileucel manufacturing is fully internalized.

Top Penny Stocks To Add to Your Watchlist - February 24th

Larimar Therapeutics, Iovance Biotherapeutics, and Mana Capital Acquisition are the three Penny stocks to watch today, according to MarketBeat's stock screener tool. Penny stocks are low-priced...

Iovance Biotherapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of cell therapies as novel cancer immunotherapy products. Its lead product candidate, LN-144 for metastatic melanoma, is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.

Iovance Biotherapeutics Inc

Beat EPS and revenue

Beat EPS, miss revenue

Miss EPS, beat revenue

Miss EPS and revenue

What do you expect from $MDB earnings today?

Current Price	$3.81
Prev Close	$3.86
Open	$3.70
Dividend Yield	0.00%
50-Day Moving Average	$2.70
Beta	1.64
Avg. Volume	12.83M
PE Ratio	-3.44

52-Week High	$4.57
52-Week Low	$1.64
Market Capitalization	$1.59B
EPS (Annual)	-$1.09
Price to Book	2.28
Revenue Per Employee	$270,258.46

IOVA
Iovance Biotherapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest IOVA News

IOVAIovance Biotherapeutics Inc